Gavestinel: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
'''Gavestinel''' | {{DISPLAYTITLE:Gavestinel}} | ||
== Gavestinel == | |||
[[File:Gavestinel.svg|thumb|right|Chemical structure of Gavestinel]] | |||
'''Gavestinel''' is a chemical compound that acts as a selective antagonist of the [[NMDA receptor]], specifically targeting the [[glycine]] site of the receptor. It was investigated for its potential use in the treatment of [[stroke]] and other [[neurological disorders]]. | |||
== Mechanism of Action == | == Mechanism of Action == | ||
Gavestinel | Gavestinel functions by inhibiting the activity of the NMDA receptor, a type of [[glutamate receptor]] that plays a crucial role in [[synaptic plasticity]] and [[neurotransmission]]. By blocking the glycine site, Gavestinel reduces the excitotoxicity associated with excessive NMDA receptor activation, which is a common pathological feature in conditions such as stroke. | ||
== Clinical | == Clinical Development == | ||
Gavestinel | Gavestinel was developed as a neuroprotective agent with the aim of reducing brain damage following an acute ischemic stroke. Despite promising preclinical results, clinical trials did not demonstrate significant efficacy in improving outcomes for stroke patients. As a result, its development for this indication was discontinued. | ||
== | == Pharmacokinetics == | ||
The | The pharmacokinetic profile of Gavestinel includes its absorption, distribution, metabolism, and excretion. It is known to cross the [[blood-brain barrier]], which is essential for its action on central nervous system targets. However, specific details on its half-life and metabolic pathways are less documented in the literature. | ||
== | == Potential Applications == | ||
Although Gavestinel was not successful in clinical trials for stroke, its mechanism of action suggests potential applications in other neurological conditions where NMDA receptor-mediated excitotoxicity is implicated, such as [[traumatic brain injury]] and certain types of [[epilepsy]]. | |||
== See Also == | == See Also == | ||
* [[NMDA receptor antagonist]] | |||
* [[Excitotoxicity]] | |||
* [[Neuroprotection]] | |||
== Related Pages == | |||
* [[Stroke]] | * [[Stroke]] | ||
* [[ | * [[Glycine receptor]] | ||
* [[ | * [[Glutamate]] | ||
[[Category:NMDA receptor antagonists]] | |||
[[Category:Neuroprotective agents]] | |||
Latest revision as of 04:01, 13 February 2025
Gavestinel[edit]
Gavestinel is a chemical compound that acts as a selective antagonist of the NMDA receptor, specifically targeting the glycine site of the receptor. It was investigated for its potential use in the treatment of stroke and other neurological disorders.
Mechanism of Action[edit]
Gavestinel functions by inhibiting the activity of the NMDA receptor, a type of glutamate receptor that plays a crucial role in synaptic plasticity and neurotransmission. By blocking the glycine site, Gavestinel reduces the excitotoxicity associated with excessive NMDA receptor activation, which is a common pathological feature in conditions such as stroke.
Clinical Development[edit]
Gavestinel was developed as a neuroprotective agent with the aim of reducing brain damage following an acute ischemic stroke. Despite promising preclinical results, clinical trials did not demonstrate significant efficacy in improving outcomes for stroke patients. As a result, its development for this indication was discontinued.
Pharmacokinetics[edit]
The pharmacokinetic profile of Gavestinel includes its absorption, distribution, metabolism, and excretion. It is known to cross the blood-brain barrier, which is essential for its action on central nervous system targets. However, specific details on its half-life and metabolic pathways are less documented in the literature.
Potential Applications[edit]
Although Gavestinel was not successful in clinical trials for stroke, its mechanism of action suggests potential applications in other neurological conditions where NMDA receptor-mediated excitotoxicity is implicated, such as traumatic brain injury and certain types of epilepsy.
